First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Recommendation of “Buy” from Brokerages

First Tracks Biotherapeutics (NASDAQ:TRAX) has earned an average recommendation of “Buy” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $39.4286.

A number of equities analysts recently commented on the stock. Zacks Research raised shares of First Tracks Biotherapeutics to a “hold” rating in a research note on Monday, April 27th. Barclays began coverage on shares of First Tracks Biotherapeutics in a report on Wednesday, April 22nd. They issued an “overweight” rating and a $40.00 price target on the stock. HC Wainwright began coverage on shares of First Tracks Biotherapeutics in a report on Tuesday, April 28th. They issued a “buy” rating and a $30.00 price target on the stock. Piper Sandler began coverage on shares of First Tracks Biotherapeutics in a report on Monday, May 4th. They issued an “overweight” rating and a $54.00 price target on the stock. Finally, Wedbush began coverage on shares of First Tracks Biotherapeutics in a report on Friday, April 24th. They issued an “outperform” rating and a $30.00 price target on the stock.

First Tracks Biotherapeutics Price Performance

Shares of NASDAQ:TRAX opened at $17.18 on Friday. First Tracks Biotherapeutics has a 52 week low of $14.79 and a 52 week high of $26.80.